NCT03851913招募中3 期
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy: A Random, Controlled, Stage III Clinical Trial
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 344 人开始时间: 2018年7月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 344
- 试验地点
- 1
- 主要终点
- OS
研究概览
简要总结
To compare the impact on survival of neo-adjuvant TAI for patients with beyond Milan criteria BCLC stage A/B HCC who underwent hepatectomy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •older than 18 years old and younger than 75 years;
- •ECOG PS≤1;
- •proven hepatocellular carcinoma according patological examination or EASL/AASLD diagnostic criteria;
- •not previous treated for tumor;
- •the tumor was diagnosed as BCLC stage A/B and beyond Milan criteria;
- •no distant metastasis;
- •the lab test could meet:
- •neutrophil count≥2.0×109/L;
- •hemoglobin≥100g/L;
- •platelet count≥75×109/L;
- •serum albumin≥35g/L;
- •total bilirubin<2-times upper limit of normal;
- •ALT<3-times upper limit of normal;
- •AST<3-times upper limit of normal;
- •serum creatine<1.5-times upper limit of normal;
- •PT≤upper limit of normal plus 4 seconds;
- •sign up consent.
排除标准
- •cannot tolerate TAI or surgery;
- •distant metastasis exits;
- •known history of other malignancy;
- •be allergic to related drugs;
- •underwent organ transplantation before;
- •be treated before (interferon included);
- •known history of HIV infection;
- •known history of drug or alcohol abuse;
- •have GI hemorrhage or cardiac/brain vascular events within 30 days;
- •pregnancy.
结局指标
主要结局
OS
时间窗: From date of randomization until the date of death from any cause, assessed up to 60 months
overall survival
次要结局
- RFS(From date of randomization until the date of recurrence, assessed up to 60 months)
- recurrence rate(1 year, 2 year, 3 year, 5 year after surgery)
- PFS(From date of randomization until the date of progression, assessed up to 60 months)
研究者
Rong-ping Guo
Professor
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
招募中
3 期
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.Hepatocellular CarcinomaNCT03368651Sun Yat-sen University230
招募中
3 期
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.Hepatocellular CarcinomaNCT03192618Sun Yat-sen University290
已完成
不适用
Comparison outcome and survival between neoadjuvant chemotherapy and primary surgery in advanced stage ovarian cancer fallopian tube cancer and peritoneal cancer:propensity score methodsOvarian cancer is second most common in gynecologic malignancies, but ismost common cause of death in gynecologic malignancies. Almost were advance stage at first visit and delay hospitalization due to late symptoms. Patients had poor outcome.treatment and high rate recurrent and dead. Poor quality of life due to many times surgeryand many chemotherapy regimen.Ovarian Cancer, Neoadjuvant Chemotherapy, Primary Surgery, CompleteRemission, Survival, Propensity ScoreTCTR20220225007Surin cancer center220
尚未招募
不适用
Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung CancerNon-small Cell Lung Cancer Stage ⅢANon-small Cell Lung Cancer Stage IIIBNCT06394427West China Hospital250
Unknown
不适用
The Effect of Neoadjuvant Chemotherapy on Locally Advanced Gastric CancerGastric CancerNCT01444755Haydarpasa Numune Training and Research Hospital80